3 Top Picks For Marijuana Stocks Investors To See Profits In 2026
For marijuana stock investors, the way the industry as a whole progresses determines a great deal for them. For example, no one wants to invest in a struggling industry even if it's been trendy along the way. Now, cannabis has fallen to that path, but it's also what's making this industry one of the hottest sectors in the last 5 years. Legal cannabis has been a long uphill battle in every sense. Legislation and regulatory issues remain the biggest challenges.
Trump's Rescheduling of Marijuana Is a Spark for Top Marijuana ETFs
After amassing enormous losses over the past five years, cannabis stocks received a much-needed shot in the arm last week when President Donald Trump announced plans to officially reschedule marijuana from Schedule I to Schedule III under the Controlled Substances Act (CSA).
Focus: Companies with cannabis-based drugs eye IPOs, private funding boost after US reclassification
Companies developing cannabis-based medicines say U.S. moves to loosen restrictions on the drug could unlock private funding and the public markets, providing a lifeline to the struggling cannabis industry.
Top U.S. Marijuana Stocks to Watch in April 2026 as the Sector Heats Up
The U.S. cannabis sector continues showing strong long-term growth potential in 2026. The legal market continues to expand across multiple states. In fact, the industry is projected to grow significantly over the next decade. Additionally, more states continue moving toward legalization in some form.
Why MJ Is No Longer A Sell
Amplify Alternative Harvest ETF is upgraded from Sell to Hold after a 33% decline, reflecting improved valuation but persistent sector risks. MJ's structure remains highly concentrated, with over half in CNBS and significant exposure to MSOs and Canadian LPs, driving volatility. Key upside catalysts include potential 280E tax elimination and Canadian cultivation tax reform, but regulatory uncertainty remains high.
Sell The MJ ETF
Amplify Alternative Harvest ETF has a history of underperformance and recent gains driven by speculative cannabis sector optimism. MJ's portfolio is concentrated in both U.S. MSOs and Canadian LPs, with heavy exposure to stocks currently rated Sell or Strong Sell. Despite recent outperformance versus peers, MJ's index construction and lack of ancillary exposure make it unattractive compared to alternatives like CNBS.
